A large number of pharmaceutical stocks ushered in the trend of reducing their holdings, and the industry called to guard against the risk of speculation

[pharmaceutical network market analysis] recently, a large number of pharmaceutical stocks are in the trend of reducing their holdings Shareholders, executives and even employees of the major listed companies are involved in it, and the stock price is also constantly callback Recently, Longjin Pharmaceutical Co., Ltd issued three consecutive share reduction announcements, successively disclosing that Yunnan huixinsheng, the major shareholder of the company, intends to reduce its holding by no more than 4% of the company's shares, Qunxing investment, the controlling shareholder of the company, fan Xianru, the actual controller, plans to reduce its holding by no more than 3% of the company's shares, and Lixing industrial, the major shareholder of the company, plans to reduce its holding by no more than 4% As for the continuous reduction, Longjin pharmaceutical said that the reason for the reduction is its own business capital needs On February 14, industrial investment group, a major shareholder of Watson biology, reduced its stake by 1.98% through block trading It is understood that in 2019, the company disclosed the reduction plan On August 22, 2019, Watson biology released the pre disclosure announcement on the reduction of shares held by shareholders holding more than 5% and their concerted actors, which shows that Liu Junhui and his concerted actor Huang Jing plan to reduce the shares of listed companies by means of centralized bidding and block trading within 6 months after 15 trading days from the disclosure of the pre disclosure announcement on the reduction of shares (no more than 1.5% of the total share capital of the listed company) At present, Liu Junhui and Huang Jing are still in the process of implementing the above share reduction plan Lexin medical recently announced that on February 18, 2020, the company received pan Weichao's notice on the progress of the implementation of the share reduction plan From February 14, 2020 to February 17, 2020, pan Weichao reduced 2.236 shares of the company by bulk trading, with the cumulative share reduction ratio reaching 1.1614% of the company's total share capital On February 3, the first trading day after the Spring Festival, Tailong Pharmaceutical Co., Ltd and other "double Huanglian concept shares" jointly closed the trading limit However, Wu Lan, the second largest shareholder of Tailong Pharmaceutical Co., Ltd., who holds 6.02% of the shares, issued a notice that night, saying that it plans to reduce its holding of no more than 6 million shares within 6 months after the 15 trading days from now, and the proportion of reduction shall not exceed 1.05% of the total share capital of the company Taking Ling pharmaceutical as the beneficiary of the epidemic, the company also issued a major shareholder reduction plan announcement In the evening of February 3, Yiling pharmaceutical announced that Lianhua Qingwen capsule / granule, the company's traditional Chinese medicine product, was listed as the recommended drug for medical observation At the same time, another announcement disclosed by Yiling pharmaceutical industry shows that Tian Shuyan, the company's shareholder, plans to reduce his holding by no more than 8.9 million shares In addition to the reduction of major shareholders and executives, Haiwang biological also ushered in the reduction period of employee stock ownership plan According to the recent announcement of Haiwang biology, 1.39% of the company's shares held in the 2017 phase I employee stock ownership plan were sold on February 6, with a cash out of about 270 million yuan The industry calls to guard against the risk of speculation In recent days, the pharmaceutical manufacturing sector has mostly declined Among the individual stocks, the shares of Haiwang biology, poten, Lianhuan pharmaceutical, Harbin pharmaceutical, etc., which were previously highly praised by the fund, have seen a continuous decline in the stock price in recent days In the rise of these pharmaceutical stocks, the company has repeatedly pointed out the relevant risks Industry insiders called for the need to guard against the risk of short-term speculation, and said that a small number of companies can reflect their performance In addition, it should be noted that the overall valuation of a shares is still in a low position, and its overall systematic growth space exists